Percutaneous Coronary Intervention (PCI): Past, Present and Future

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Cardiovascular Medicine".

Deadline for manuscript submissions: 31 March 2024 | Viewed by 3318

Special Issue Editors

Department of Advanced Biomedical Sciences, Federico II University of Naples, 80131 Naples, Italy
Interests: percutaneous coronary intervention; coronary artery disease; peripheral artery disease; antithrombotic therapy
1. Department of Advanced Biomedical Sciences, University of Naples Federico II, 80131 Naples, Italy
2. CPC Clinical Research, Department of Medicine, University of Colorado, Aurora, CO 80045, USA
Interests: clinical cardiology; heart failure; coronary artery disease; antithrombotic therapy; peripheral arterial disease
1. Department of Advanced Biomedical Sciences, University of Naples Federico II, 80131 Naples, Italy
2. Quebec Heart and Lung Institute, Laval University, Quebec City, QC G1V0A6, Canada
Interests: transcatheter aortic valve replacement; transcatheter aortic valve implantation; percutaneous coronary intervention; coronary artery disease; antithrombotic therapy

Special Issue Information

Dear Colleagues,

Percutaneous coronary intervention (PCI) represents the most common strategy to manage flow-limiting coronary artery stenoses. According to the latest evidence from large randomized or observational studies, PCI continues to improve with an ever-broadening indication in light of the newer devices and procedural techniques, which has led higher rates of successful procedures and improved clinical outcomes over time. PCI has also been offered to more complex patients including those at high-risk or with cardiogenic shock, eventually through devices for mechanical support. Hence, a PCI strategy guided by physiology, imaging, and optimal lesion management should be pursued to obtain complete revascularization and sustained long-term results. In addition, the refinement of antithrombotic therapy in patients undergoing PCI has contributed to further improving patient outcomes; however, its optimization remains a matter of ongoing debate in order to balance ischemic and bleeding risks.

The aim of the present Special Issue is to offer insights into the implementation of diagnosis and treatment of patients with coronary artery disease (CAD), covering several aspects of interventional cardiology from procedural techniques to peri-procedural management. The intended primary target audience consists of clinicians who are involved in the care of patients for whom revascularization is indicated. The Editors hope that this Special Issue will be of interest to interventional cardiologists as well as a broader range of clinicians that encounter CAD. Therefore, we invite researchers and clinicians to submit their works, including original clinical research studies, meta-analyses, and reviews, related to the PCI field.

Prof. Dr. Giuseppe Gargiulo
Dr. Mario Enrico Canonico
Dr. Marisa Avvedimento
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • coronary revascularization
  • percutaneous coronary intervention (PCI)
  • coronary artery disease
  • acute coronary syndrome
  • chronic coronary syndrome
  • antithrombotic therapy

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

15 pages, 809 KiB  
Review
Antithrombotic Therapy Optimization in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
by Felice Gragnano, Antonio Capolongo, Antonio Micari, Francesco Costa, Victoria Garcia-Ruiz, Vincenzo De Sio, Fabrizia Terracciano, Arturo Cesaro, Elisabetta Moscarella, Silvio Coletta, Pasquale Raucci, Fabio Fimiani, Leonardo De Luca, Giuseppe Gargiulo, Giuseppe Andò and Paolo Calabrò
J. Clin. Med. 2024, 13(1), 98; https://doi.org/10.3390/jcm13010098 - 23 Dec 2023
Viewed by 2996
Abstract
The antithrombotic management of patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) poses numerous challenges. Triple antithrombotic therapy (TAT), which combines dual antiplatelet therapy (DAPT) with oral anticoagulation (OAC), provides anti-ischemic protection but increases the risk of bleeding. Therefore, TAT is [...] Read more.
The antithrombotic management of patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) poses numerous challenges. Triple antithrombotic therapy (TAT), which combines dual antiplatelet therapy (DAPT) with oral anticoagulation (OAC), provides anti-ischemic protection but increases the risk of bleeding. Therefore, TAT is generally limited to a short phase (1 week) after PCI, followed by aspirin withdrawal and continuation of 6–12 months of dual antithrombotic therapy (DAT), comprising OAC plus clopidogrel, followed by OAC alone. This pharmacological approach has been shown to mitigate bleeding risk while preserving adequate anti-ischemic efficacy. However, the decision-making process remains complex in elderly patients and those with co-morbidities, significantly influencing ischemic and bleeding risk. In this review, we discuss the available evidence in this area from randomized clinical trials and meta-analyses for post-procedural antithrombotic therapies in patients with non-valvular AF undergoing PCI. Full article
(This article belongs to the Special Issue Percutaneous Coronary Intervention (PCI): Past, Present and Future)
Show Figures

Figure 1

Back to TopTop